RU2011105073A - Вирусоподобные частицы (впч) вируса гриппа, содержащие гемагглютинин - Google Patents
Вирусоподобные частицы (впч) вируса гриппа, содержащие гемагглютинин Download PDFInfo
- Publication number
- RU2011105073A RU2011105073A RU2011105073/10A RU2011105073A RU2011105073A RU 2011105073 A RU2011105073 A RU 2011105073A RU 2011105073/10 A RU2011105073/10 A RU 2011105073/10A RU 2011105073 A RU2011105073 A RU 2011105073A RU 2011105073 A RU2011105073 A RU 2011105073A
- Authority
- RU
- Russia
- Prior art keywords
- plant
- nucleic acid
- virus
- influenza virus
- stage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H5/00—Angiosperms, i.e. flowering plants, characterised by their plant parts; Angiosperms characterised otherwise than by their botanic taxonomy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
- C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y503/00—Intramolecular oxidoreductases (5.3)
- C12Y503/04—Intramolecular oxidoreductases (5.3) transposing S-S bonds (5.3.4)
- C12Y503/04001—Protein disulfide-isomerase (5.3.4.1), i.e. disufide bond-forming enzyme
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F9/00—Arrangements for program control, e.g. control units
- G06F9/06—Arrangements for program control, e.g. control units using stored programs, i.e. using an internal store of processing equipment to receive or retain programs
- G06F9/46—Multiprogramming arrangements
- G06F9/50—Allocation of resources, e.g. of the central processing unit [CPU]
- G06F9/5005—Allocation of resources, e.g. of the central processing unit [CPU] to service a request
- G06F9/5027—Allocation of resources, e.g. of the central processing unit [CPU] to service a request the resource being a machine, e.g. CPUs, Servers, Terminals
- G06F9/505—Allocation of resources, e.g. of the central processing unit [CPU] to service a request the resource being a machine, e.g. CPUs, Servers, Terminals considering the load
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16223—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/65—Vector systems having a special element relevant for transcription from plants
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F2209/00—Indexing scheme relating to G06F9/00
- G06F2209/50—Indexing scheme relating to G06F9/50
- G06F2209/508—Monitor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Software Systems (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Theoretical Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Physiology (AREA)
- Botany (AREA)
Abstract
1. Нуклеиновая кислота, включающая последовательность нуклеотидов, кодирующую гемагглютинин вируса гриппа (НА), по меньшей мере на 70% идентичная SEQ ID NO: 28, оперативно связанную с регуляторным участком, активным в растении. ! 2. Нуклеиновая кислота по п.1, у которой НА включает нативный или ненативный сигнальный пептид. ! 3. Нуклеиновая кислота по п.2, у которой ненативный сигнальный пептид представляет собой сигнальный пептид протеиндисульфидизомеразы. ! 4. Нуклеиновая кислота по п.1, у которой вирус гриппа представляет собой вирус гриппа типа А/Калифорния/04/09. ! 5. Способ получения вирусоподобных частиц (ВЧ) вируса гриппа в растении, включающий: ! а) введение нуклеиновой кислоты по п.1 в растение или его часть и ! б) инкубирование растения или его части в условиях, позволяющих экспрессию нуклеиновой кислоты, получая таким образом ВЧ. ! 6. Способ по п.5, при котором на стадии введения (стадия а) нуклеиновая кислота экспрессируется в растении временным образом. ! 7. Способ по п.5, при котором на стадии введения (стадия а) нуклеиновая кислота экспрессируется в растении стабильным образом. ! 8. Способ по п.5, включающий также стадию с) сбора растения-хозяина и очистку ВЧ. ! 9. Способ по п.5, при котором на стадии введения (стадия а) в растение вводится вторая нуклеиновая кислота, включающая последовательность нуклеотидов, кодирующую один или более белок шаперон. ! 10. Способ по п.9, при котором один или более белок шаперон выбирается из группы, состоящей из Hsp40 и Hsp70. ! 11. Способ получения вирусоподобных частиц (ВЧ) вируса гриппа в растении, включающий: ! а) получение растения или части растения, содержащей нуклеиновую кислоту по п.1 и ! б) инкуби
Claims (24)
1. Нуклеиновая кислота, включающая последовательность нуклеотидов, кодирующую гемагглютинин вируса гриппа (НА), по меньшей мере на 70% идентичная SEQ ID NO: 28, оперативно связанную с регуляторным участком, активным в растении.
2. Нуклеиновая кислота по п.1, у которой НА включает нативный или ненативный сигнальный пептид.
3. Нуклеиновая кислота по п.2, у которой ненативный сигнальный пептид представляет собой сигнальный пептид протеиндисульфидизомеразы.
4. Нуклеиновая кислота по п.1, у которой вирус гриппа представляет собой вирус гриппа типа А/Калифорния/04/09.
5. Способ получения вирусоподобных частиц (ВЧ) вируса гриппа в растении, включающий:
а) введение нуклеиновой кислоты по п.1 в растение или его часть и
б) инкубирование растения или его части в условиях, позволяющих экспрессию нуклеиновой кислоты, получая таким образом ВЧ.
6. Способ по п.5, при котором на стадии введения (стадия а) нуклеиновая кислота экспрессируется в растении временным образом.
7. Способ по п.5, при котором на стадии введения (стадия а) нуклеиновая кислота экспрессируется в растении стабильным образом.
8. Способ по п.5, включающий также стадию с) сбора растения-хозяина и очистку ВЧ.
9. Способ по п.5, при котором на стадии введения (стадия а) в растение вводится вторая нуклеиновая кислота, включающая последовательность нуклеотидов, кодирующую один или более белок шаперон.
10. Способ по п.9, при котором один или более белок шаперон выбирается из группы, состоящей из Hsp40 и Hsp70.
11. Способ получения вирусоподобных частиц (ВЧ) вируса гриппа в растении, включающий:
а) получение растения или части растения, содержащей нуклеиновую кислоту по п.1 и
б) инкубирование растения или его части в условиях, позволяющих экспрессию нуклеиновой кислоты, получая таким образом ВЧ.
12. Растение, содержащее нуклеиновую кислоту по п.1.
13. Растение по п.12, содержащее дополнительно нуклеиновую кислоту, включающую последовательность нуклеотидов, кодирующую один или более белок-шаперон, оперативно связанную с регуляторным участком, активным в растении.
14. Растение по п.12, в котором один или более белок-шаперон выбирают из группы, состоящей из Hsp40 и Hsp70.
15. Вирусоподобная частица (ВЧ), полученная в растении, содержащая белок НА вируса гриппа, по меньшей мере на 70% идентичный SEQ ID NO: 28 и один или более одного липид растительного происхождения.
16. Вирусоподобная частица по п.15, у которой вирус гриппа представляет собой вирус гриппа типа А/Калифорния/04/09.
17. Композиция, содержащая эффективную дозу вирусоподобной частицы по п.15 и фармацевтически приемлемый носитель.
18. Способ индуцирования иммунитета против инфицирования вирусом гриппа у субъекта, состоящий во введении вирусоподобной частицы по п.15.
19. Способ по п.18, при котором вирусоподобную частицу вводят субъекту перорально, внутрикожно, интраназально, внутримышечно, внутрибрюшинно, внутривенно или подкожно.
20. Вирусоподобная частица (ВЧ), полученная в растении, содержащая НА вируса гриппа, по меньшей мере на 70% идентичный SEQ ID NO: 28, несущий N-гликаны или модифицированные N-гликаны, специфичные для растений.
21. Вирусоподобная частица по п.20, у которой вирус гриппа представляет собой вирус гриппа типа А/Калифорния/04/09.
22. Композиция, содержащая эффективную дозу ВЧ по п.21 и фармацевтически приемлемый носитель.
23. Способ индуцирования иммунитета против инфицирования вирусом гриппа у субъекта, состоящий во введении композиции по п.22.
24. Способ по п.23, при котором вирусоподобную частицу вводят субъекту перорально, внутрикожно, интраназально, внутримышечно, внутрибрюшинно, внутривенно или подкожно.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CA2008/001281 WO2009009876A1 (en) | 2007-07-13 | 2008-07-11 | Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant |
CAPCT/CA2008/001281 | 2008-07-11 | ||
PCT/CA2009/000032 WO2009076778A1 (en) | 2007-11-27 | 2009-01-12 | Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin |
CAPCT/CA2009/000032 | 2009-01-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2011105073A true RU2011105073A (ru) | 2012-08-20 |
Family
ID=41507811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011105073/10A RU2011105073A (ru) | 2008-07-11 | 2009-07-02 | Вирусоподобные частицы (впч) вируса гриппа, содержащие гемагглютинин |
Country Status (15)
Country | Link |
---|---|
EP (2) | EP2307549A4 (ru) |
JP (1) | JP5921884B2 (ru) |
KR (2) | KR101956910B1 (ru) |
CN (1) | CN102272308A (ru) |
AU (1) | AU2009267759A1 (ru) |
BR (1) | BRPI0915896A2 (ru) |
CA (1) | CA2730185C (ru) |
EA (1) | EA034733B1 (ru) |
ES (1) | ES2525177T3 (ru) |
IL (1) | IL210215A (ru) |
MX (1) | MX2011000459A (ru) |
NZ (1) | NZ590144A (ru) |
RU (1) | RU2011105073A (ru) |
SG (1) | SG187500A1 (ru) |
WO (1) | WO2010003225A1 (ru) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2571223C2 (ru) * | 2009-09-18 | 2015-12-20 | Фронхофер Юэсэй Инк. | Вирусоподобные частицы, содержащие белки-мишени, слитые с белками оболочки растительных вирусов |
US9815873B2 (en) | 2011-03-23 | 2017-11-14 | Medicago Inc. | Method for recovering plant-derived proteins |
US11826419B2 (en) | 2009-09-22 | 2023-11-28 | Medicago Inc. | Method of preparing plant-derived VLPs |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2615372A1 (en) | 2007-07-13 | 2009-01-13 | Marc-Andre D'aoust | Influenza virus-like particles (vlps) comprising hemagglutinin |
CN103122354B (zh) | 2007-11-27 | 2018-03-23 | 麦迪卡格公司 | 表达血凝素之转基因植物中生产的重组流感病毒样颗粒(vlp) |
WO2009151407A2 (en) * | 2008-06-14 | 2009-12-17 | Veredus Laboratories Pte Ltd | Influenza sequences |
WO2010003235A1 (en) | 2008-07-08 | 2010-01-14 | Medicago Inc. | Soluble recombinant influenza antigens |
DK2318530T3 (en) | 2008-07-18 | 2016-10-03 | Medicago Inc | Ny epitope to immunization against influenza |
NZ597401A (en) | 2009-06-24 | 2013-09-27 | Medicago Inc | Chimeric influenza virus-like particles comprising hemagglutinin |
AU2011325827B2 (en) | 2010-11-04 | 2016-08-04 | Medicago Inc. | Plant expression system |
TWI526539B (zh) | 2010-12-22 | 2016-03-21 | 苜蓿股份有限公司 | 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp |
KR20140047069A (ko) * | 2011-06-20 | 2014-04-21 | 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 계산에 최적화된 광범위 반응을 나타내는 h1n1 인플루엔자를 위한 항원 |
SI2734545T1 (sl) | 2011-07-18 | 2019-06-28 | Institute For Research In Biomedicine | Protitelesa, ki nevtralizirajo virus influence A in njihova uporaba |
US11155581B2 (en) | 2011-09-30 | 2021-10-26 | Medicago Inc. | Increasing virus-like particle yield in plants |
US11390878B2 (en) | 2011-09-30 | 2022-07-19 | Medicago Inc. | Increasing protein yield in plants |
WO2013068593A1 (en) * | 2011-11-11 | 2013-05-16 | Philip Morris Products S.A. | Influenza virus -like particles (vlps) comprising hemagglutinin produced nicotiana tabacum |
EP2812348A4 (en) * | 2012-02-07 | 2015-12-30 | Univ Pittsburgh | ANTIGENS WITH BROAD SPECTRUM OPTIMIZED IN SILICO FOR INFLUENZA VIRUSES OF TYPE H3N2, H2N2 AND B |
SG11201406153XA (en) | 2012-03-30 | 2014-10-30 | Univ Pittsburgh | Computationally optimized broadly reactive antigens for h5n1 and h1n1 influenza viruses |
RU2693431C2 (ru) | 2012-09-05 | 2019-07-02 | Медикаго Инк. | Получение пикорнавирусоподобных частиц в растениях |
IN2015DN03070A (ru) | 2012-11-27 | 2015-10-02 | Univ Pittsburgh | |
CN105247059B (zh) * | 2013-03-28 | 2021-07-06 | 莫迪卡戈公司 | 植物中流感样病毒颗粒的产生 |
BR112016015875A2 (pt) | 2014-01-10 | 2017-09-19 | Medicago Inc | Elementos intensificadores de cpmv |
ES2912291T3 (es) | 2014-03-27 | 2022-05-25 | Medicago Inc | Elementos potenciadores de CPMV modificados |
ES2787042T3 (es) | 2014-07-11 | 2020-10-14 | Medicago Inc | Modificación de la producción de proteínas en plantas |
WO2016168187A1 (en) * | 2015-04-13 | 2016-10-20 | The Regents Of The University Of Michigan | Virus-like particles |
CA2987939A1 (en) | 2015-06-02 | 2016-12-08 | Sanofi Pasteur Inc. | Engineered influenza antigenic polypeptides and immunogenic compositions thereof |
CN107920487A (zh) | 2015-07-02 | 2018-04-17 | 莫迪卡戈公司 | 茉莉酸通路激活剂 |
CA3026096A1 (en) | 2016-06-02 | 2017-12-07 | Sanofi Pasteur Inc. | Engineered influenza antigenic polypeptides and immunogenic compositions thereof |
JP6622825B2 (ja) * | 2018-01-25 | 2019-12-18 | インスティテュート・フォー・リサーチ・イン・バイオメディシンInstitute For Research In Biomedicine | A型インフルエンザウイルス中和抗体及びその使用法 |
WO2020000101A1 (en) * | 2018-06-27 | 2020-01-02 | Medicago Inc. | Influenza virus hemagglutinin mutants |
WO2020092207A1 (en) * | 2018-10-28 | 2020-05-07 | University Of Georgia Research Foundation | Broadly reactive immunogens of influenza virus, compositions, and methods of use thereof |
BR112021017602A2 (pt) * | 2019-03-06 | 2021-11-16 | Plantform Corp | Vetores de t-dna com sequências 5' engenheiradas a montante de enzimas de modificação pós-tradução e métodos de uso das mesmas |
BR112021017899A2 (pt) | 2019-03-14 | 2021-12-21 | Medicago Inc | Intensificador de expressão vegetal endógeno |
JP2020048568A (ja) * | 2019-11-22 | 2020-04-02 | インスティテュート・フォー・リサーチ・イン・バイオメディシンInstitute For Research In Biomedicine | A型インフルエンザウイルス中和抗体及びその使用法 |
US20230203101A1 (en) * | 2020-04-22 | 2023-06-29 | POSTECH Research and Business Development Foundation | Coronavirus Disease 2019(COVID -19) Recombinant Spike Protein Forming Trimer, Method for Mass Producing Recombinant Spike Protein in Plants, and Method for Preparing Vaccine Composition on Basis Thereof |
EP4351320A1 (en) | 2021-06-09 | 2024-04-17 | ImmunityBio, Inc. | Methods and systems for producing a protein of interest in a plant |
CN114891074B (zh) * | 2022-05-10 | 2023-04-11 | 中山大学·深圳 | 一种季节性甲型流感通用病毒样颗粒及其制备方法与应用 |
CN115992101B (zh) * | 2023-03-22 | 2023-07-28 | 深圳市卫光生物制品股份有限公司 | 一种流感病毒裂解疫苗原液的制备方法 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5428147A (en) | 1983-04-15 | 1995-06-27 | Mycogen Plant Science, Inc. | Octopine T-DNA promoters |
US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US5100792A (en) | 1984-11-13 | 1992-03-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues |
US5036006A (en) | 1984-11-13 | 1991-07-30 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US4962028A (en) | 1986-07-09 | 1990-10-09 | Dna Plant Technology Corporation | Plant promotors |
US5232833A (en) | 1988-09-14 | 1993-08-03 | Stressgen Biotechnologies Corporation | Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants |
US6403865B1 (en) | 1990-08-24 | 2002-06-11 | Syngenta Investment Corp. | Method of producing transgenic maize using direct transformation of commercially important genotypes |
UA48104C2 (ru) | 1991-10-04 | 2002-08-15 | Новартіс Аг | Фрагмент днк, содержащий последовательность, которая кодирует инсектицидный протеин, оптимизированную для кукурузы, фрагмент днк, обеспечивающий направленную желательную для сердцевины стебля экспрессию связанного с ней структурного гена в растении, фрагмент днк, обеспечивающий специфическую для пыльцы экспрессию связанного с ней структурного гена в растении, рекомбинантная молекула днк, способ получения оптимизированной для кукурузы кодирующей последовательности инсектицидного протеина, способ защиты растений кукурузы по меньшей мере от одного насекомого-вредителя |
KR100797667B1 (ko) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | 외래 유전자의 전사를 조절하는 방법 |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
WO2002000885A2 (en) * | 2000-06-23 | 2002-01-03 | American Cyanamid Company | Assembly of wild-type and chimeric influenza virus-like particles (vlps) |
AU2004235800B2 (en) | 2003-05-05 | 2010-02-18 | Dow Agrosciences Llc | Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production |
ZA200508930B (en) | 2003-05-05 | 2007-03-28 | Thompson Boyce Inst Plant Research | Vectors and cells for preparing immunoprotective compositions derived from transgenic plants |
US8592197B2 (en) * | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
CN100410378C (zh) * | 2005-05-09 | 2008-08-13 | 中国农业科学院生物技术研究所 | 编码禽流感血凝素的基因及其植物表达载体和应用 |
CA2615658A1 (en) * | 2005-07-19 | 2007-01-25 | Dow Global Technolgies Inc. | Recombinant flu vaccines |
CA2650091A1 (en) * | 2006-04-21 | 2008-05-22 | Dow Agrosciences Llc | Vaccine for avian influenza and methods of use |
US8778353B2 (en) * | 2006-05-01 | 2014-07-15 | Technovax, Inc. | Influenza virus-like particle (VLP) compositions |
EP2029755A1 (en) | 2006-05-22 | 2009-03-04 | Plant Bioscience Limited | Bipartite system, method and composition for the constitutive and inducible expression of high levels of foreign proteins in plants |
KR100964462B1 (ko) * | 2007-07-10 | 2010-06-16 | 성균관대학교산학협력단 | 형질전환 식물 유래의 조류독감 바이러스 백신 및 그 제조방법 |
-
2009
- 2009-01-12 KR KR1020167010959A patent/KR101956910B1/ko active IP Right Grant
- 2009-01-12 SG SG2013004577A patent/SG187500A1/en unknown
- 2009-01-12 EA EA201001198A patent/EA034733B1/ru not_active IP Right Cessation
- 2009-07-02 RU RU2011105073/10A patent/RU2011105073A/ru not_active Application Discontinuation
- 2009-07-02 AU AU2009267759A patent/AU2009267759A1/en not_active Abandoned
- 2009-07-02 ES ES12181077.4T patent/ES2525177T3/es active Active
- 2009-07-02 CA CA2730185A patent/CA2730185C/en active Active
- 2009-07-02 JP JP2011516934A patent/JP5921884B2/ja active Active
- 2009-07-02 WO PCT/CA2009/000926 patent/WO2010003225A1/en active Application Filing
- 2009-07-02 EP EP09793741A patent/EP2307549A4/en not_active Withdrawn
- 2009-07-02 BR BRPI0915896A patent/BRPI0915896A2/pt not_active IP Right Cessation
- 2009-07-02 EP EP12181077.4A patent/EP2570484B1/en active Active
- 2009-07-02 KR KR1020117001798A patent/KR20110034650A/ko not_active Application Discontinuation
- 2009-07-02 MX MX2011000459A patent/MX2011000459A/es not_active Application Discontinuation
- 2009-07-02 CN CN2009801348688A patent/CN102272308A/zh active Pending
- 2009-07-02 NZ NZ590144A patent/NZ590144A/xx not_active IP Right Cessation
-
2010
- 2010-12-23 IL IL210215A patent/IL210215A/en not_active IP Right Cessation
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2571223C2 (ru) * | 2009-09-18 | 2015-12-20 | Фронхофер Юэсэй Инк. | Вирусоподобные частицы, содержащие белки-мишени, слитые с белками оболочки растительных вирусов |
US11826419B2 (en) | 2009-09-22 | 2023-11-28 | Medicago Inc. | Method of preparing plant-derived VLPs |
US11833200B2 (en) | 2009-09-22 | 2023-12-05 | Medicago Inc. | Method of preparing plant-derived proteins |
US9815873B2 (en) | 2011-03-23 | 2017-11-14 | Medicago Inc. | Method for recovering plant-derived proteins |
Also Published As
Publication number | Publication date |
---|---|
MX2011000459A (es) | 2011-02-23 |
NZ590144A (en) | 2012-11-30 |
CN102272308A (zh) | 2011-12-07 |
ES2525177T3 (es) | 2014-12-18 |
KR20110034650A (ko) | 2011-04-05 |
BRPI0915896A2 (pt) | 2019-09-24 |
WO2010003225A1 (en) | 2010-01-14 |
EA201001198A1 (ru) | 2011-06-30 |
CA2730185C (en) | 2016-02-09 |
IL210215A0 (en) | 2011-03-31 |
JP2011527180A (ja) | 2011-10-27 |
EP2307549A1 (en) | 2011-04-13 |
WO2010003225A8 (en) | 2010-07-22 |
EA034733B1 (ru) | 2020-03-13 |
SG187500A1 (en) | 2013-02-28 |
IL210215A (en) | 2013-11-28 |
CA2730185A1 (en) | 2010-01-14 |
EP2570484A1 (en) | 2013-03-20 |
KR20160049061A (ko) | 2016-05-04 |
AU2009267759A1 (en) | 2010-01-14 |
JP5921884B2 (ja) | 2016-05-24 |
EP2570484B1 (en) | 2014-09-10 |
KR101956910B1 (ko) | 2019-03-12 |
EP2307549A4 (en) | 2011-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2011105073A (ru) | Вирусоподобные частицы (впч) вируса гриппа, содержащие гемагглютинин | |
ES2378409T3 (es) | Método para producir sustancias biológicas en cultivo sin proteínas | |
EP1358319B1 (en) | Live influenza vaccine and method of manufacture | |
CA2762042A1 (en) | Chimeric influenza virus-like particles comprising hemagglutinin | |
JP6113155B2 (ja) | 計算で最適化した広い反応性を示すh1n1インフルエンザの抗原 | |
JP2022066209A (ja) | Mdck、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス | |
RU2014116371A (ru) | Повышение выхода вирусоподобных частиц в растениях | |
EP3393508A1 (en) | Zika virus purification | |
RU2013154698A (ru) | Получение вирусоподобной частицы вируса бешенства в растениях | |
AU2002223560A1 (en) | Live influenza vaccine and method of manufacture | |
JP2012530499A5 (ru) | ||
RU2015146097A (ru) | Получение вирусоподобных частиц вируса гриппа в растениях | |
CN104395336A (zh) | 以计算方式优化的h5n1和h1n1流感病毒的广泛反应性抗原 | |
EP4093415A1 (en) | Recombinant influenza viruses with stabilized na | |
US5756341A (en) | Method for controlling the infectivity of viruses | |
WO2011134163A1 (zh) | 一种h9n2亚型禽流感灭活疫苗的制备方法及产品 | |
RU2358981C2 (ru) | Универсальная вакцина против вируса гриппа птиц | |
JP5978172B2 (ja) | ウイルスの増殖のための二段階温度プロフィール | |
CN111057683A (zh) | 一种鸡胚接种用病毒稀释液及其制备方法和应用 | |
RU2020143530A (ru) | Мутанты гемагглютинина вируса гриппа | |
RU2020143519A (ru) | Мутанты гемагглютинина вируса гриппа | |
RU2020143526A (ru) | Мутанты гемагглютинина вируса гриппа | |
Masurel et al. | Vaccination and protection experiments in mice with the human A-1957 and A-1968 strains, and the Equi-2 strain of influenza virus | |
RU2631129C1 (ru) | Способ изготовления вакцины против ящура и вакцина против ящура | |
RU2024107147A (ru) | Вирусоподобная частица fmdv со стабилизирующей мутацией |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20140801 |